Liraglutide

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
MUC, Human, Biotechnology, CSPC, Drug discovery, Carcinoma, Cervical cancer, Rash, Patient, MMAE, Tumor microenvironment, Peripheral neuropathy, IND, PH1b, Insulin resistance, Investment, Investigational New Drug, Therapy, CB1, ATM, Safety, Liraglutide, CMO, FDA, PD-1, Pharmaceutical industry

We expect to dose the first patient in our US Ph1 study in March 2024.

Key Points: 
  • We expect to dose the first patient in our US Ph1 study in March 2024.
  • For CRB-601, the FDA cleared our Investigational New Drug (“IND”) application in January 2024, and we expect to dose the first patient this summer.
  • The Company presented CRB-913 pre-clinical data at Obesity Week as an oral presentation and as a late breaking poster in October 2023.
  • The Company is currently conducting IND enabling studies and expects to file an IND in the fourth quarter of 2024.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Multimedia, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024
Liver, School, Liraglutide, Metformin, SCM, GDF15, HKBU, Artesunate, Research, Blood, Obesity, FDA, Fatty liver disease, Exercise, Nausea, Food, GDNF, Trial of the century, Health, Human, Safety, GFRAL, Associate, Patient, Fasting, Insulin, Nature Communications, Tissue, Appetite, Hong Kong Baptist University, Mouse, Public, Pharmaceutical industry

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Fitness & Nutrition, Pharmaceutical, Clinical Trials, Poster, Weight loss, Pharmacokinetics, Human, Investigational New Drug, Obesity, Patient, IND, Fasting, Keystone, Myostatin, GDF11, Mouse, Rock, MPH, Food, SMA, Body composition, Immunoglobulin G, Nandi (Hinduism), Doctor of Philosophy, Liraglutide, ELISA, Dietary supplement

“These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.

Key Points: 
  • “These preclinical data showing that SRK-439 preserves lean mass and improves fat mass loss provide compelling scientific rationale to study SRK-439 in combination with GLP-1 RA therapies for healthy weight loss management,” said Jay Backstrom, M.D., MPH, President and CEO of Scholar Rock.
  • “We believe that preserving lean muscle mass through our highly selective approach to myostatin inhibition in combination with GLP-1 RA therapy has the potential to transform the management of weight loss.
  • In parallel, Scholar Rock is developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity.
  • SRK-439 also improved fat mass loss (–36.60% to –46.32% from baseline with semaglutide; –17.31% to –19.04% from baseline with liraglutide).

Slim Pickings: Finding Cost-Effective Obesity Solutions

Retrieved on: 
Monday, January 8, 2024
Quality of life, Motivation, ICER, Goldman Sachs, Glucagon, Vegetable, Gross domestic product, Overweight, Multimedia, Type 2, Dark Ages, Weight loss, Hypertension, Diet, BMI, Depression, Person, Insulin, Pancreas, Diabetes, Trial of the century, Research, Human, Eye, Obesity, Fertility, Deoxycholic acid, Behavior, Insurance, Absenteeism, Food, Type 2 diabetes, Patient, Liraglutide, Therapy, Urbanization, Automation, Dopamine, Exercise, Orlistat, Environment, Dietary supplement

NEW YORK, Jan. 8, 2024 /PRNewswire-PRWeb/ -- During the Middle Ages and Renaissance, a full figure was a symbol of status, indicating one's wealth, fertility and power in an environment of food scarcity. Today, it has a negative connotation. Faced with antiquity's unreliable resources, humans were hardwired to prioritize calorie-dense, energy-rich foods. To reinforce this behavior, evolution gave a boost of dopamine to big eaters; those who failed to feast during times of plenty might starve when food ran out. While abundant calorie consumption was an advantage in early societies, the ingrained drive to stock up is now a liability as access to food has become more reliable.

Key Points: 
  • Obesity presents many health risks, and expensive GLP-1 agonists have grabbed the limelight, but there are affordable and effective ways to address it.
  • While this behavior was a boon during times of food instability, constant consumption of energy dense nourishment now contributes to obesity.
  • Obesity not only increases health risks and reduces quality of life and mobility; but also produces a significant economic impact.
  • This requires alternative approaches and comprehensive efforts that combine cost-effective medications with diet and exercise to reduce excessive obesity rates.

Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes

Retrieved on: 
Wednesday, November 15, 2023
Diet, Physician, Liraglutide, Insulin, Exercise, Clinical trial, Overweight, T2D, CGM, DSM-IV codes, Week, Type 2 diabetes, Obesity, Therapy, MD, Doctor of Philosophy, Diabetes, Medical imaging, Medical device, T1D, Philosopher's stone

BERKELEY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, today announced that it has commenced a Phase 2 clinical trial of its once-daily dual GLP-1/GIP receptor agonist, CT-868, in adult participants with overweight or obesity with T1D.

Key Points: 
  • In addition to the Phase 2 clinical trial announced today, Carmot has an ongoing Phase 1b active comparator crossover clinical trial to assess the effects of CT-868 treatment on glucose homeostasis compared to liraglutide in participants with T1D.
  • CT-868 is one of three clinical-stage product candidates in Carmot’s pipeline of therapeutics for the potential treatment of obesity and diabetes.
  • Carmot anticipates enrolling approximately 95 participants at clinical trial centers across the United States.
  • Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels, diet and exercise recommendations.

Amide Technologies Announces Complex Peptide Manufacturing Platform, Raises $16.5M to Expedite Frontier Drug Discovery

Retrieved on: 
Thursday, December 14, 2023
Professional Services, Health, Other Professional Services, Other Health, Finance, Pharmaceutical, Biotechnology, Peptide, Dicarboxylic acid, SPPS, Acquisition, DNA, Liraglutide, Organization, Therapy, MIT, Velia, ITA Software, Dulaglutide, Flight, Leuprorelin, Protein, Multimedia, AFPS, Infection, Biology, FDA, General partnership, CIO, Drug design, Structural biology, Goserelin, Hand, Drug discovery, Ginkgo Bioworks, Doctor of Philosophy, Cancer, Diabetes, Type 2, Chemistry, Fine chemical, Amide

Amide Technologies , a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform.

Key Points: 
  • Amide Technologies , a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform.
  • New advances in structural biology, recombinant biologics, and AI-driven technologies have improved drug design and delivery methods, overcoming many previous pharmacokinetic behavior drawbacks of peptides .
  • “Amide delivers on complex peptide orders that other vendors refuse because peptide sourcing shouldn’t stand in the way of discovery,” said Amide CEO Mark Simon, PhD.
  • ITA Software founder and CEO Jeremy Wertheimer is an Amide co-founder and Board Member, alongside MIT Professor of Chemistry Brad Pentelute, PhD.

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2023

Retrieved on: 
Monday, December 18, 2023
Medicine, Vomiting, Brain, Liraglutide, European Commission, Pseudoephedrine, Semaglutide, RCVS, PRES, Headache, Dulaglutide, Allergy, Kidney disease, State, EMA, Civil service commission, Signal, Patient, DSM-IV codes, Exenatide, Association, RMP, Vaccine, CHMP, Reversible cerebral vasoconstriction syndrome, Marketing, Data, COVID-19, Seizure, Diagnosis, Communication, Direct, Health care, Review, Failure, PRAC, Confusion, Public, Pharmaceutical industry, Hospital, Dietary supplement, Medical device, Safety

EMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior reversible encephalopathy syndrome (PRES)…, Agenda Agenda of the PRAC meeting 27-30 November 2023DraftFirst published: 27/11/2023Reference Number: EMA/PRAC/477373/2023…, PRAC statistics: December 2023, Glossary:Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

Key Points: 


EMA’s safety committee, PRAC, has recommended new measures for medicines containing pseudoephedrine to minimise the risks of posterior reversible encephalopathy syndrome (PRES)…, Agenda Agenda of the PRAC meeting 27-30 November 2023DraftFirst published: 27/11/2023Reference Number: EMA/PRAC/477373/2023…, PRAC statistics: December 2023, Glossary:Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

Rising Diabetes Cases Drive Robust Growth in the Global Glucagon-like Peptide 1 (GLP-1) Market: A CAGR of 6.48% Expected - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Diabetes, Pharmaceutical, Health, Eli Lilly and Company, Ageing, Plasma, Half-life, AstraZeneca, Food, Obesity, Hypothalamus, Non-alcoholic fatty liver disease, Weight loss, Prevalence, Research, Exercise, Type 2 diabetes, Enzyme, Inflammation, Pfizer, Fatty liver disease, Conditional sentence, NASH, Thirst, COVID-19, Risk, DPP, Glucagon-like peptide-1, Diet, Liraglutide, NAFLD, Dulaglutide, Sanofi, Safety, Patient, Compound annual growth rate, Novo Nordisk, Appetite, Insulin, Dietary supplement, Pharmaceutical industry, Semaglutide

GLP-1 receptor agonists represent a class of non-insulin medications employed in conjunction with diet and exercise to manage type 2 diabetes.

Key Points: 
  • GLP-1 receptor agonists represent a class of non-insulin medications employed in conjunction with diet and exercise to manage type 2 diabetes.
  • Trulicity holds the largest market share due to the increasing prevalence of type 2 diabetes, driving demand for effective treatments.
  • The global GLP-1 market encompasses five major regions: North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa.
  • The prevalence of diabetes has surged, particularly in low- and middle-income countries, boosting demand for diabetes medication, thereby propelling the global GLP-1 market.

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Rimonabant, NSCLC, Food, Biomarker, Doctor of Philosophy, CB1, Breast cancer, University of Virginia Cancer Center, SITC, The Obesity Society, Head, CSPC, FACP, Human, Therapeutic index, Cleavage, Yale School of Medicine, Society for Immunotherapy of Cancer, Mouse, DIO, Immunotherapy, University, Hand, Investment, Patient, Monoclonal antibody, Food and Drug Administration Amendments Act of 2007, Plasma, Conference, Liraglutide, Development, ADC, Brain, Insulin resistance, Society, AACR, IND, Manuscript, Poster, MMAE, Semaglutide, Tumor microenvironment, Carcinoma, Mab, Neck, Medical imaging, Vaccine, Soft drink, Pharmaceutical industry, Corbus, MD, Obesity

“The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Finally, we presented the first ever comprehensive data on CRB-913, our highly peripherally restricted cannabinoid type-1 receptor (CB1) inverse agonist.
  • Early clinical experience will be shared in Q1 2024, which will coincide with the initiation of a U.S./EU trial by Corbus.
  • Corbus presented two posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held on November 1 - 5, 2023.